Skip to main content
. Author manuscript; available in PMC: 2018 Jan 10.
Published in final edited form as: Circulation. 2017 Jan 10;135(2):180–195. doi: 10.1161/CIRCULATIONAHA.116.022622

Figure 3. Time horizon to benefit for intensive glycemic control for intermediate microvascular outcomes.

Figure 3

The composite microvascular endpoint was defined as retinopathy requiring photocoagulation, presence of vitreous hemorrhage, and or fatal or non-fatal renal failure defined as an elevated creatinine >2.8 mg/dL. Reprinted from the Lancet, 352(9131), 837–853, Copyright ©1998, with permission from Elsevier.27